SCHEMBL5566290

SCHEMBL5566290

C=C(C(=O)c1ccc(S(=O)(=O)NC)cc1)c1cc(-c2cc3ccccc3n2C)c(OC)cc1OC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.35
MEN1 O00255 2/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
KMT2A Q03164 2/20 0.35
HPGD P15428 1/20 0.35
RECQL P46063 1/20 0.35
FLT1 P17948 1/20 0.35
FLT4 P35916 1/20 0.35
KDR P35968 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
BRD1 O95696 1/20 0.34
BRPF1 P55201 1/20 0.34
BRPF3 Q9ULD4 1/20 0.34
NLRP3 Q96P20 1/20 0.34
PTGER3 P43115 1/20 0.34
LMNA P02545 1/20 0.34
KAT6A Q92794 1/20 0.33
RORC P51449 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5565582 0.93 PTGER3 (0.36) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL5565781 0.92 ALDH1A1 (0.35) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL6040934 0.89 CA2 (0.41) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL5564936 0.88 AKR1C3 (0.36) KDM4EALDH1A1FLT1FLT4KDR
SCHEMBL5565819 0.88 GAA (0.40) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL5565465 0.86 IMPDH2 (0.33) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL6040695 0.86 KMT2A (0.40) KDM4EMEN1ALDH1A1MAPTKMT2A
SCHEMBL5565784 0.85 HPGD (0.52) ALDH1A1KMT2AHPGDKDRLMNA
SCHEMBL5565826 0.85 HPGD (0.51) ALDH1A1KMT2AHPGDKDRLMNA
SCHEMBL5564750 0.84 PKM (0.46) MEN1ALDH1A1MAPTKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US claimed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US claimed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 US claimed
WO-2004108094-A2 SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES ATHEROGENICS, INC. (US) 2004-12-16 WO claimed
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHEROGENICS, INC. (US) 2007-04-26 US disclosed
US-7173129-B2 Sulfonamide-substituted chalcone derivatives and their use to treat diseases ATHERO GENICS, INC. (US) 2007-02-06 US disclosed
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases CRABTREE ACQUISITION CO, LLC 2005-03-03 US disclosed
WO-2004108094-A2 SULFONAMIDE-SUBSTITUTED CHALCONE DERIVATIVES AND THEIR USE TO TREAT DISEASES ATHEROGENICS, INC. (US) 2004-12-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050049236-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 KDM4E 2383/4885MEN1 2929/4885ALDH1A1 1653/4885
US-20070093453-A1 Sulfonamide-substituted chalcone derivatives and their use to treat diseases STS, HPSE, SULT1E1 KDM4E 2383/4885MEN1 2929/4885ALDH1A1 1653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.